Effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase compared with GnRH agonist long protocol in non-obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI.
10.5653/cerm.2012.39.1.22
- Author:
Chung Hoon KIM
1
;
Jei Won MOON
;
Hyuk Jae KANG
;
Jun Woo AHN
;
Sung Hoon KIM
;
Hee Dong CHAE
;
Byung Moon KANG
Author Information
1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. chnkim@amc.seoul.kr
- Publication Type:Original Article ; In Vitro ; Randomized Controlled Trial
- Keywords:
Polycystic ovary syndrome;
GnRH antagonist;
GnRH agonist;
Body mass index;
Controlled ovarian stimulation;
In vitro fertilization
- MeSH:
Body Mass Index;
Female;
Fertilization in Vitro;
Follicle Stimulating Hormone, Human;
Follicular Phase;
Gonadotropin-Releasing Hormone;
Humans;
Incidence;
Ovarian Hyperstimulation Syndrome;
Ovulation Induction;
Polycystic Ovary Syndrome;
Pregnancy;
Pregnancy Outcome
- From:Clinical and Experimental Reproductive Medicine
2012;39(1):22-27
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: To evaluate the effectiveness of GnRH antagonist multiple dose protocol applied during early and late follicular phase (MDP-EL) in comparison with standard GnRH agonist luteal long protocol (LP) in each non-obese and obese polycystic ovary syndrome (PCOS) women undergoing IVF. METHODS: Two hundred eleven infertile women with PCOS were recruited and randomized to undergo either GnRH antagonist MDP-EL (antagonist group) or standard GnRH agonist luteal LP (agonist group). IVF cycle outcomes were compared between the two groups. RESULTS: Total dose and days of recombinant human follicle stimulating hormone (rhFSH) administered were significantly fewer in the antagonist group than in the agonist group. Incidence of severe ovarian hyperstimulation syndrome was significantly lower in the antagonist group. However, IVF and pregnancy outcomes were similar in the two groups. When all subjects were divided into non-obese and obese subgroups, in non-obese PCOS subgroup, IVF and pregnancy outcomes were comparable in the antagonist and agonist groups but total dose and days of rhFSH were also significantly fewer in the antagonist group. Similar findings were also observed in obese PCOS subgroup. CONCLUSION: GnRH antagonist MDP-EL is at least as effective as GnRH agonist LP and may be a more patient-friendly alternative in controlled ovarian stimulation for PCOS patients undergoing IVF, independent of body mass index.
